文献速递MDS 与骨髓增殖性肿瘤

性别决定MPN的表现和结局,并与突变负荷的性别差异相关

Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden.
PubMed 文献 · Blood Adv · 2020-01-01

该研究纳入2005至2019年间815例原发性血小板增多症、真性红细胞增多症或原发性骨髓纤维化患者,评估性别与表现型、JAK2 V617F负荷、进展和生存的关联。男性是MPN不良结局的独立预测因素,可能与非MPN特异性体细胞突变(尤其高危突变)风险增加有关,而非MPN特异性突变等位基因频率。

要点

  • 男性更常表现为原发性骨髓纤维化而非原发性血小板增多症(相对风险3.2;P<.001)和真性红细胞增多症(相对风险2.1;P<.001)。
  • 男性转化为继发性骨髓纤维化(HR 1.55;P=.013)和急性髓系白血病(HR 3.67;P<.001)的风险更高,生存更差(HR 1.63;P=.001)。
  • 男性CD34+细胞中JAK2 V617F等位基因负荷更高(P=.001),获得更多体细胞突变(P=.012),1个(OR 2.35;P=.017)和2个(OR 20.20;P=.011)高危突变频率增加。

核心结论

  • 男性是MPN不良结局的独立预测因素。
  • 这似乎是由于非MPN特异性体细胞突变(尤其高危突变)风险增加,而非MPN特异性突变等位基因频率。
  • 女性疾病进展更依赖JAK2突变等位基因负荷而非获得其他体细胞突变。
  • 性别应被考虑在MPN的预后模型和治疗策略评估中。

研究设计与样本

  • 研究纳入2005至2019年间815例原发性血小板增多症、真性红细胞增多症或原发性骨髓纤维化患者,评估性别与表现型、JAK2 V617F负荷、进展和生存的关联。

主要发现

  • 男性更常表现为原发性骨髓纤维化而非原发性血小板增多症(相对风险3.2;P<.001)和真性红细胞增多症(相对风险2.1;P<.001)。
  • 男性转化为继发性骨髓纤维化(HR 1.55;P=.013)和急性髓系白血病(HR 3.67;P<.001)的风险更高,生存更差(HR 1.63;P=.001),独立于年龄、诊断时表现型和MPN特异性突变。
  • 男性CD34+细胞中JAK2 V617F等位基因负荷更高(P=.001),获得更多体细胞突变(P=.012),1个(OR 2.35;P=.017)和2个(OR 20.20;P=.011)高危突变频率增加,独立于年龄、表现型和驱动突变。
  • 女性疾病进展更依赖JAK2突变等位基因负荷而非获得其他体细胞突变。

临床怎么用

  • 作者认为性别应被考虑在MPN的预后模型和治疗策略评估中。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The factors underlying the variable presentation and clinical course of myeloproliferative neoplasms (MPNs) remain unclear. The aim of this study was to evaluate the independent effect of sex on MPN presentation and outcomes. A total of 815 patients with essential thrombocytosis, polycythemia vera, or primary myelofibrosis were evaluated between 2005 and 2019, and the association of sex with presenting phenotype, JAK2 V617F burden, progression, and survival was examined. Men presented more often with primary myelofibrosis vs essential thrombocytosis (relative risk, 3.2; P < .001) and polycythemia vera (relative risk, 2.1; P < .001), had higher rates of transformation to secondary myelofibrosis (hazard ratio [HR], 1.55; P = .013) and acute myeloid leukemia (HR, 3.67; P < .001), and worse survival (HR, 1.63; P = .001) independent of age, phenotype at diagnosis, and MPN-specific mutation. Men had higher JAK2 V617F allele burdens in their CD34+ cells (P = .001), acquired more somatic mutations (P = .012) apart from the MPN-specific mutations, and had an increased frequency of 1 (odds ratio, 2.35; P = .017) and 2 (odds ratio, 20.20; P = .011) high-risk mutations independent of age, phenotype, and driver mutation. Male sex is an independent predictor of poor outcomes in MPNs. This seems to be due to an increased risk of non-MPN-specific somatic mutations, particularly high-risk mutations, rather than MPN-specific mutation allele frequency. Conversely, disease progression in female subjects is more dependent on JAK2 mutation allele burden than on acquisition of other somatic mutations. Sex should be considered in prognostic models and when evaluating therapeutic strategies in MPNs.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Karantanos T, Chaturvedi S, Braunstein EM, et al. Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. Blood Adv. 2020. PMID: 32542392. doi:10.1182/bloodadvances.2019001407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。